Estimates Revisions Xilio Therapeutics, Inc.
Stocks
XLO
US98422T2096
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.150 USD | -0.76% |
|
+1.10% | +2.09% |
| 06-29 | Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index | CI |
| 06-29 | Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
- Stock Market
- Stocks
- XLO Stock
- Consensus Xilio Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
